bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.06.04.729731

Fasting Status and Epigenetic Clock Stability: Implications for Aging Research

Abstract

BackgroundEpigenetic clocks are DNA methylation-based biomarkers increasingly used in aging research and clinical trials. A recent assessment of 18 clocks across multiple short-term perturbations concluded that most demonstrate only moderate biological reliability, raising concerns about their translational utility. However, epigenetic clocks differ substantially in their construction and in the biological signals they capture, and their sensitivity to physiological perturbation may not be a flaw but a consequence of the construction. To understand this more clearly, we undertook a focused investigation of biological reliability for a single, well-characterised perturbation, an overnight fast followed by acute refeeding, examining how and why clock estimates may shift with physiological state. MethodsWe evaluated 24 epigenetic clocks spanning five construction categories - first and second generation classical clocks (eg. Horvath, Hannum, PhenoAge), the PC versions of the classical clocks, SystemsAge organ-system clocks, mortality-trained clocks (GrimAge, PCGrimAge, OMICmAge), pace of aging clocks (DunedinPACE) and the IntrinClock, across three datasets: a within-person paired fasting design (n = 15 pairs), a cross-sectional cohort of fasted vs non-fasted (n = 2,895), and EPICv2custom technical replicates (n = 96 samples from 4 individuals). For each clock, we quantified the acute fasting effect with and without immune cell adjustment, decomposed between-person and within-person variance at successive adjustment levels (Raw, EAA, IAA), and benchmarked biological variability against the technical measurement floor. ResultsFasting followed by acute refeeding was associated with group-level shifts of 0.5-3 years in immune-sensitive clocks, while within-person reliability remained high (Raw clock ICC median ~0.96). These observations are compatible because fasting effects are small relative to the age-driven between-person variance that dominates the ICC denominator. The magnitude of the observed shift varied by clock. PC transformations showed larger effects than their classical counterparts in the paired cohort (PC Hannum -2.03 vs. Hannum -1.37 years; PC PhenoAge > PhenoAge; PC Horvath > Horvath), SystemsAge showed the largest effects (1.15-2.9 years younger when fasted), and mortality-trained clocks (GrimAge V1/V2, OMICmAge) and DunedinPACE showed no detectable acute effect (all FDR p > 0.10). Immune cell adjustment attenuated or eliminated the fasting effects in sensitive clocks (PC Hannum 88% attenuation; SystemsAge Blood 99.7%); no clock retained a significant fasting effect after FDR-corrected immune adjustment in either cohort. Within the cross-sectional cohort, a clocks immune content, which is the fraction of its age-independent variance explained by immune cell composition, was correlated with the degree to which immune adjustment attenuated its fasting effect (r = 0.68, p = 0.003). IntrinClock, designed to exclude immune-variable CpGs, showed no fasting effect in either cohort (immune R2 = 3.2%), serving as a negative control. Technical replicates confirmed near-perfect measurement reproducibility (median Raw ICC > 0.97), establishing that variance in fasting pairs reflects biology, not noise. Immune-adjusted ICCs behaved differently across clocks in ways consistent with their composition: for clocks where fasting generated within-person variance, immune adjustment removed it and ICC increased (SystemsAge EAA 0.768 to IAA 0.913); for clocks unaffected by fasting, immune adjustment removed between-person structure and ICC fell substantially (OMICmAge 0.922 to 0.160), reflecting the estimation cost of fitting many immune cell predictors to stable residuals. Cross-sectional replication (n = 2,895) confirmed immune cell redistribution at scale. Mortality clocks reached significance cross-sectionally despite resistance to acute fasting. ConclusionsEpigenetic clock responses to an overnight fast followed by acute refeeding varied systematically by training category in our data. PC-based clocks, which concentrate correlated CpG variance including that associated with immune cell composition, showed the largest shifts; mortality-trained clocks showed no detectable acute effect. A framework that summarises a clock by its ICC alone, without identifying the biological source of its within-person variation, can misread structured, perturbation-driven biology as measurement noise. ICC is not a fixed property of a clock, it is shaped by the study design, the population heterogeneity, the perturbation, and the adjustment applied. We recommend that clock reliability be assessed on a perturbation-specific, clock-by-clock basis, with variance decomposition at each adjustment level and explicit benchmarking against technical replicates.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Seale, K. B., Dwaraka, V. B., Giosan, I., Mendez, T., Smith, R.. 2026-06-07. Fasting Status and Epigenetic Clock Stability: Implications for Aging Research. https://doi.org/10.64898/2026.06.04.729731

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗